Treatment of renal allograft rejection with T10B9.1A31 or OKT3: Final analysis of a phase II clinical trial

Transplantation

Volumn 64, Issue 2, 1997, Pages 274-281

  Waid, Thomas H ^a   Lucas, Bruce A ^a   Thompson, John S ^a   McKeown, J Wade ^a   Brown, Stephen ^a   Kryscio, Richard ^a   Skeeters, Lisa J ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYTOKINE; DIPHENHYDRAMINE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY T10B9; OKT 3; PARACETAMOL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAARTERIAL DRUG ADMINISTRATION; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL; CYCLOSPORINE; CYTOKINES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MUROMONAB-CD3; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; VIRUS DISEASES;

EID: 0030750396     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199707270-00017     Document Type: Article

References (43)

1. Campana D, Thompson JS, Amlot P, Brown S, Jannossy G. The cryoplasmic expression of CD3 antigens in normal and malignant cells of the T-lymphoid lineage. J Immunol 1987; 138: 648.
2. Henslee J, Byers U, Jennings CD, et al. Update on the in vivo administration of a lymphocyte targeted immunotoxin, xomazyme H65 for graft-versus-host prophylaxis following histo-in-compatible partially T-depleted marrow grafts. Transplant Proc 1989; 21: 3004.
3. Waid TH, Lucas BA, Amlot P, et al. T10B9.1A-31 anti T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection. Am J Kidney Dis 1989; 14: 61.
4. Waid TH, Lucas BA, Thompson JS, et al. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 1992; 53: 80.
5. Kaplan EI, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457.
6. Takemoto S, Gjertson DW, Terasaki PJ. HLA matching: maximizing the number of compatible transplants. In: Terasaki PI, Cecka JM, eds. Clinical transplants 1993. Los Angeles, CA: UCLA Tissue Typing Laboratory, 1993: 521.
7. Kirkman RL, Araujo JL, Busch GJ, et al. Treatment of acute renal allograft rejection with monoclonal anti-t12 antibody. Transplantation 1983; 36: 620.
8. Hale G, Waldmann H, Friend P, et al. Pilot study of CAM-PATH-1, a rat monoclonal antibody that fixes human complement as an immunosuppressant in organ transplantation. Transplantation 1986; 42: 308.
9. Linch DB, Beverly PCL, Newland A, et al. Treatment of low grade T-cell proliferation with monoclonal antibody. Clin Exp Immunol 1983; 51: 133.
10. Tax WJM, van de Heijden GMW, Willems HW, et al. Immunosuppression with monoclonal antiT3 antibody (WT32) in renal transplantation. Transplant Proc 1987; 19: 1905.
11. Takahasi H, Terasaki PI, Kinukawa T, et al. Reversal of transplant rejection by monoclonal antiblast antibody. Lancet 1983; 2: 1115.
12. Hoistma AJ. The diagnostic and therapeutic usefulness of monoclonal anti-T-cell antibodies in human transplantation: results of a workshop. Transplant Proc 1986; 18: 1303.
13. Friend PJ, Tighe H, Lim S, et al. The use of monoclonal antibodies against activated human T cells following renal allografting in the baboon. Transplant Proc 1987; 19: 4317.
14. Jonker M, Nooji FJM, Chatenoud L. Immunosuppression by monoclonal T cell antibodies. Transplant Proc 1986; 18: 1287.
15. 8F treatment on allograft survival in rhesus monkeys. Transplantation 1986; 41: 431.
16. Jonker M, Nooji FJM, Steinhoff G. Effects of CD4 and CD8 specific monoclonal antibodies in vitro and in vivo on T cells and their relation to the allograft response in rhesus monkeys. Transplant Proc 1987; 19: 4308.
17. Norman DJ, Bennett WM, Cobanoglu A, et al. Use of OKT4 (a murine monoclonal anti-CD5 antibody) in human organ transplantation: initial clinical experience. Transplant Proc 1993; 25: 802.
18. d'Apice AJF, Thurlow PJ, Ihle BV, Lovering EK, McKenzie IFC. Treatment of acute renal allograft rejection with a monoclonal antibody to a T-cell antigen (HuLy-M2). Aust NZ J Med 1987; 17: 210.
19. Lazarovits AI, Roden J, Banks L, et al. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. J Immunol 1993; 150: 5163.
20. Cosimi AB, Burton RR, Colvin RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32: 535.
21. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1987; 313: 337.
22. Thistlethwaite JR, Cosimi AB, Delmonico FL, et al. Evolving use of OKT3 monoclonal antibody for treatment of allograft rejection. Transplantation 1984; 38: 695.
23. Norman DJ, Barry JM, Hennell K. Reversal of acute allograft rejection with monoclonal antibody. Transplant Proc 1985; 17: 39.
24. 3 antibody orthoclone OKT3 to kidney allograft recipients. Transplant Proc 1986; 17: 2734.
25. 3 antibody for acute cadaveric renal allograft rejection. Transplantation 1984; 38: 489.
26. Hirsch RL, Layton PC, Barnes LA, et al. Orthoclone OKT3 treatment of acute renal allograft rejection in patients receiving maintenance cyclosporine therapy. Transplant Proc 1987; 19: 32.
27. Bristow MR, Gilbert EM, O'Connell JB, et al. OKT3 monoclonal antibody in heart transplantation. Am J Kidney Dis 1988; 11: 135.
28. Bristow MR, Renlund DG, Gilbert EM. Murine monoclonal CD3 antibody in cardiac transplantation: antirejection treatment and preliminary results in a prospectively randomized trial for prophylaxis. Clin Transplant 1988; 2: 163.
29. Smely S, Weschka M, Hillebrand G, et al. Prophylactic use of the new monoclonal antibody BMA 031 in clinical kidney transplantation. Transplant Proc 1990; 22: 1785.
30. Pfeffer PF, Jakobsen A, Albrechtsen D, et al. BMA 031 effectively reverses steroid-resistant rejection in renal transplants. Transplant Proc 1991; 23: 1099.
31. Pfeffer PF, Ohlman S, Jakobsen A, et al. A Scandinavian two-center study of BMA 031 in steroid-resistant rejection of renal grafts. Transplantation 1993; 56: 304.
32. Knight RJ, Kurrle R, McClain J, et al. Clinical evaluation of induction immunosuppression with a murine IgG/2b monoclonal antibody (BMA 031) directed toward the human αα-T cell receptor. Transplantation 1994; 56: 1581.
33. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-tac monoclonal antibody in human renal transplantation. Transplantation 1991; 51: 107.
34. Soulillou JP, Cantarovich D, LeMauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175.
35. Reding R, Vraux H, deGoyet JDV, et al. Monoclonal antibodies in prophylactic immunosuppression after liver transplantation: a randomized controlled trial comparing OKT3 and anti-IL2 receptor monoclonal antibody LO-Tact-1. Transplantation 1993; 55: 534.
36. Catarovich D, LeMauff B, Hourmant M, et al. Anti-interleukin 2 receptor monoclonal antibody in the treatment of ongoing acute rejection episodes of human kidney graft: a pilot study. Transplantation 1989; 47: 454.
37. Waid TH, Lucas BA, Thompson JS, et al. Treatment of acute cellular kidney allograft rejection with T10B9.1A31 anti T-cell monoclonal antibody. Transplant Proc 1989; 21: 1778.
38. Waid TH, Lucas BA, Thompson JS, et al. Treatment of acute rejection with anti T-cell antigen receptor complex αβ (T10B9.1A-31) or anti CD3 (OKT3) monoclonal antibody: results of a prospective randomized double blind trial. Transplant Proc 1991; 23: 1062.
39. Lucas BA, Waid, TH, Thompson JS, et al. Comparison of T10B9.1A-31 and OKT3 in treating acute renal allograft rejection. Transplant Proc 1993; 25: 543.
40. Chatenoud L, Legendre C, Ferran C, Bach J, Kreis H. Corticosteroid inhibition of the OKT3-induced cytokine-released syndrome: dosage and kinetics prerequisites. Transplantation 1991; 51: 334.
41. Lindholm A, Ohlman S, DagfINn A, Tufueson G, Persson H, Persson N. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993; 56: 307.
42. Matas A, Kristen J, Payne W, Najarian J. The impact of an acute rejection episode on long-term renal allograft survival (T 1/2). Transplantation 1994; 56: 857.
43. Tesi RJ, Elmahdi AE, Henry ML, Ferguson RM. OKT3 for primary therapy of the first rejection episodes in kidney transplants. Transplantation 1992; 55: 1023.